Purpose of this Study
Participants will receive the study drug rademikibart through a brief IV infusion along with standard treatment for an asthma or COPD flare-up. Researchers will collect information about medications, smoking history, hospital stays, breathing tests, blood and urine samples, and overall health. Participants will be followed for 42 days after receiving the study drug.
Who Can Participate?
Eligibility
Participants may be able to join if they are experiencing an acute flare-up of asthma or COPD that their doctor plans to treat with steroid medication. They must also have blood test results showing inflammation. This study is not for people whose breathing problems are caused by other medical conditions.
Age Range
18-85
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
This study is testing a new medicine called rademikibart for people with asthma or COPD. Rademikibart is designed to reduce inflammation that can make breathing problems worse. Researchers want to learn how well a single dose of the drug works, how quickly it may improve breathing, and how safe it is when given during an asthma or COPD flare-up.
Locations
Duke University Hospital
Duke Regional Hospital
Visit Timing
Weekdays
Compensation
Yes
Spanish Materials Available
Yes
Study Details
Full Title
A Phase 2, Open-Label, Single-Arm Trial to Evaluate IV Rademikibart as an Add-On Treatment for an Acute Exacerbation in Participants With Asthma or COPD With Type 2 Inflammation
Principal Investigator
Alexander
Limkakeng
Protocol Number
PRO00121353
Phase
II
Enrollment Status
Pending Open to Enrollment